Post by Confo Therapeutics

First patients dosed in a Phase 2a trial of CFTX-1554, our novel AT2R antagonist for chronic pain, being developed with Lilly under our global licensing agreement. A key milestone: the first Confo-discovered candidate to enter Phase 2, advancing new non-opioid pain options. Read full article here: : https://lnkd.in/dtiANhJR #ConfoTherapeutics #ClinicalTrials #Phase2 #ChronicPain #NonOpioid #GPCR #DrugDevelopment